Full text is available at the source.
Abstract
A novel mRNA cancer vaccine utilizing supramolecular lipid nanoparticles may enhance antitumor efficacy.
- The vaccine codelivers mRNA encoding tumor antigen and a TLR7/8 agonist (R848) to dendritic cells.
- A new ionizable lipid (N2-3L) improves the translation efficiency of mRNA in the vaccine.
- R848 is encapsulated using a β-cyclodextrin-modified ionizable lipid, which promotes dendritic cell maturation.
- Enhanced dendritic cell maturation and antigen presentation after vaccination lead to improved antitumor responses.
- The vaccine's antitumor efficacy is further increased when combined with immune checkpoint blockade.
Simplified